Sage Therapeutics Inc. (SAGE)
7.46
0.09 (1.22%)
At close: Apr 17, 2025, 10:28 AM
1.22% (1D)
| Bid | 7.39 |
| Market Cap | 458.65M |
| Revenue (ttm) | 41.24M |
| Net Income (ttm) | -400.67M |
| EPS (ttm) | -6.59 |
| PE Ratio (ttm) | -1.13 |
| Forward PE | -2.84 |
| Analyst | Hold |
| Ask | 7.54 |
| Volume | 84,995 |
| Avg. Volume (20D) | 1,478,177 |
| Open | 7.33 |
| Previous Close | 7.37 |
| Day's Range | 7.33 - 7.50 |
| 52-Week Range | 4.62 - 14.97 |
| Beta | 0.48 |
About SAGE
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2014
Employees 353
Stock Exchange NASDAQ
Ticker Symbol SAGE
Website https://www.sagerx.com
Analyst Forecast
According to 18 analyst ratings, the average rating for SAGE stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 7.24% from the latest price.
Stock ForecastsNext Earnings Release
Sage Therapeutics Inc. is scheduled to release its earnings on Apr 29, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+35.14%
Sage Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
5 months ago
-24.06%
Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results. Additionally, HC Wainwright & Co. cut its price target on the stock from $25 to $14.
